$6.71
-0.1-1.47%
Last update: Nov 4, 5:13 PM
MapLight Therapeutics Inc
MPLTNASDAQ
The average analyst price target for MapLight Therapeutics is $32.45, 388.7% above the current price. Of 12 analysts, 10 rate it Buy and 2 Hold. Targets range from $13 to $46. The latest change came on Oct 6, 2026, when Guggenheim initiated coverage of MapLight Therapeutics with a Neutral rating.
Price Target Range — 4 Quarters
Analyst Consensus — 12 Analysts
Rating Trend — Last 9 Months
